Spexis provides a unique, low clinical risk, high reward investment, yet, dependent on securing sufficient funding. ColiFin, approved in the EU for cystic fibrosis (CF), needs only a single positive phase III trial to gain US approval. We forecast CHF 300+ mn ColiFin US peak sales.
Key catalysts include:
1) Strategic decision on balixafortide (H2 2022)
2) Start of ColiFin “COPILOT” dosing trial in CF (H1 2023)
3) Start of ColiFin single pivotal US phase III “COPA” trial in CF (H2 2023)